ERK Inhibitor LY3214996-Based Treatment Strategies for RAS-Driven Lung Cancer.
Ontology highlight
ABSTRACT: RAS gene mutations are the most frequent oncogenic event in lung cancer. They activate multiple RAS-centric signaling networks among them the MAPK, PI3K, and RB pathways. Within the MAPK pathway, ERK1/2 proteins exert a bottleneck function for transmitting mitogenic signals and activating cytoplasmic and nuclear targets. In view of disappointing antitumor activity and toxicity of continuously applied MEK inhibitors in patients with KRAS-mutant lung cancer, research has recently focused on ERK1/2 proteins as therapeutic targets and on ERK inhibitors for their ability to prevent bypass and feedback pathway activation. Here, we show that intermittent application of the novel and selective ATP-competitive ERK1/2 inhibitor LY3214996 exerts single-agent activity in patient-derived
SUBMITTER: Kohler J
PROVIDER: S-EPMC8026682 | biostudies-literature | 2021 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA